Patents by Inventor Hilton B. Levy

Hilton B. Levy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4389395
    Abstract: A nuclease resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid, poly-l-lysine and carboxymethylcellulose, wherein the nucleotide homopolymers have sedimentation coefficients of 4S and each homopolymer has a molecular weight of about 25,000 or less. When administered in a pharmacologically acceptable aqueous carrier, such as a saline solution, the complex is effective in inducing the synthesis of antiviral levels of interferon in the host, while modulating the toxicity reactions normally associated with the administration of greater molecular weight complexes of polyriboinosinic-polyribocytidylic acid, particularly hypotension.
    Type: Grant
    Filed: January 9, 1981
    Date of Patent: June 21, 1983
    Inventors: A. Martin Lerner, Hilton B. Levy
  • Patent number: 4349538
    Abstract: A nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid, poly-1-lysine, and carboxymethylcellulose, and injectable preparations thereof in a pharmaceutically acceptable aqueous carrier such as saline solution. When administered to a human or non-human primate host, the complex is effective in inducing the synthesis in such host of antiviral levels of interferon.
    Type: Grant
    Filed: November 18, 1980
    Date of Patent: September 14, 1982
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventor: Hilton B. Levy
  • Patent number: 4140761
    Abstract: Interferon introduced parenterally in a human host or stimulated by an inducer (PICLC) for a period of greater than 21 days results in a major decrease in all markers of infectivity, such as DNA polymerase, and such markers remain at a depressed level during the period of treatment. Where PICLC is utilized to induce interferon in the host, a serum level of 50 units per milliliter or higher is necessary for effective clinical treatment and 17 .times. 10.sup.4 - 6.0 .times. 10.sup.3 U/kg/day is an effective dose for exogenous interferon. Especially long-term treatment with exogenous interferon of greater than 21 days and up to 14 months results in clinical improvement for chronic hepatitis B virus (HBV) infection and this long-term treatment has resulted in sustained improvement even after cessation of treatment as well as resulting in a decrease in infectivity risk to others in close proximity to the infected human host. Such clinical improvement is marked by normalization of liver histology.
    Type: Grant
    Filed: April 11, 1977
    Date of Patent: February 20, 1979
    Assignee: The United States of America as represented by the Department of Health, Education & Welfare
    Inventors: John L. Gerin, Hilton B. Levy, Thomas C. Merigan, Robert H. Purcell, William S. Robinson
  • Patent number: 4024241
    Abstract: A nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid, poly-l-lysine and carboxymethylcellulose, and injectable preparations thereof in a pharmaceutically acceptable aqueous carrier such as saline solution. When administered to a primate host, the complex is effective in inducing the synthesis in such host of antiviral levels of interferon.
    Type: Grant
    Filed: September 4, 1975
    Date of Patent: May 17, 1977
    Assignee: The United States of America as represented by the Secretary of Health, Education and Welfare
    Inventor: Hilton B. Levy
  • Patent number: 3952097
    Abstract: A nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid, poly-1-lysine and carboxymethylcellulose, and injectable preparations thereof in a pharmaceutically acceptable aqueous carrier such as saline solution. When administered to a non-human primate host, the complex is effective in inducing the synthesis in such host of antiviral levels of interferon.
    Type: Grant
    Filed: September 27, 1974
    Date of Patent: April 20, 1976
    Assignee: The United States of America as represented by the Department of Health, Education and Welfare
    Inventor: Hilton B. Levy